MRTX1133 formic

MRTX1133 is a first-in-class, highly selective small molecule inhibitor targeting the KRAS G12D mutant protein in both its active and inactive states, sparing wild-type KRAS. It is a valuable research tool for investigating KRAS-driven oncology in both in vitro cellular assays and in vivo xenograft models, supporting the development of targeted cancer therapies.